Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A realworld study

被引：0
|
作者：
Yang, Xiaojian [1 ]
Quan, Penghe [1 ]
Yu, Changjiang [1 ]
机构：
[1] Air Force Mil Med Univ, XIjing Hosp, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16592
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, R.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] ALTER-H-004: A phase II study of anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post-surgery recurrence
    Wu, Z.
    Wang, Z.
    Du, X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S703 - S703
  • [33] Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients
    Lucca, Ilaria
    Roupret, Morgan
    Kluth, Luis
    Rink, Michael
    Tilki, Derya
    Fajkovic, Harun
    Kassouf, Wassim
    Hofbauer, Sebastian L.
    de Martino, Michela
    Karakiewicz, Pierre I.
    Briganti, Alberto
    Quoc-dien Trinh
    Seitz, Christian
    Fritsche, Hans-Martin
    Burger, Maximilian
    Lotan, Yair
    Kramer, Gero
    Shariat, Shahrokh F.
    Klatte, Tobias
    BJU INTERNATIONAL, 2015, 115 (05) : 722 - 727
  • [34] Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of > 1500 Patients
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2016, 195 (02): : 300 - 300
  • [35] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, P.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO
    Rexer, H.
    Retz, M.
    Albers, P.
    UROLOGE, 2016, 55 (11): : 1491 - 1493
  • [37] PURE-02: An open-label, single-arm, feasibility study of neoadjuvant pembrolizumab before Radical Nephroureterectomy (RNU) in patients with high-risk, Upper-Tract Urothelial Carcinoma (UTUC)
    Necchi, A.
    Martini, A.
    Raggi, D.
    Cucchiara, V.
    Colecchia, M.
    Luciano', R.
    Ross, J.
    Mazzone, E.
    Scuderi, S.
    Barletta, F.
    Capitanio, U.
    Salonia, A.
    Briganti, A.
    Messina, A.
    Montorsi, F.
    EUROPEAN UROLOGY, 2021, 79 : S1089 - S1089
  • [38] Efficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274
    Volkova, M., I
    Olshanskaya, A. S.
    Kalinin, S. A.
    ONKOUROLOGIYA, 2021, 17 (01): : 108 - 119
  • [39] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study
    Wang, Jiabei
    Peng, Tao
    Liu, Chang
    Zhang, Ling
    Zhu, Guangzhi
    Zhang, Xiaogang
    Wang, Xiaoqian
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Adjuvant TACE plus lenvatinib as compared with TACE alone in patients with hepatocellular carcinoma at high risk of recurrence after surgery: A prospective controlled study.
    Zhang, Bin
    Jin, Renan
    Xu, Junjie
    Chen, Ming Yu
    Chen, Jiang
    Zhu, Hepan
    Cao, Jiasheng
    Song, Chao
    Yang, Zaibo
    Zhang, Yewei
    Liang, Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 505 - 505
12345